Veracyte (VCYT) Stock Forecast, Price Target & Predictions
VCYT Stock Forecast
Veracyte stock forecast is as follows: an average price target of $35.00 (represents a -16.49% downside from VCYT’s last price of $41.91) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
VCYT Price Target
VCYT Analyst Ratings
Buy
Veracyte Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 07, 2024 | Mike Matson | Needham | $44.00 | $35.85 | 22.74% | 4.99% |
Aug 12, 2024 | Tejas Savant | Morgan Stanley | $26.00 | $29.41 | -11.58% | -37.96% |
May 04, 2022 | Morgan Stanley | $23.00 | $21.00 | 9.55% | -45.12% | |
May 04, 2022 | Needham | $26.00 | $21.46 | 21.16% | -37.96% |
Veracyte Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $44.00 | $35.00 |
Last Closing Price | $41.91 | $41.91 | $41.91 |
Upside/Downside | -100.00% | 4.99% | -16.49% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 15, 2024 | UBS | Buy | Initialise | |
Oct 10, 2024 | Guggenheim | Buy | Initialise | |
Aug 12, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
Aug 07, 2024 | Needham | Buy | Buy | Hold |
Aug 07, 2024 | William Blair | Outperform | Outperform | Hold |
Jan 05, 2023 | Scotiabank | Sector Outperform | Initialise |
Veracyte Financial Forecast
Veracyte Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $98.20M | $90.11M | $90.32M | $82.42M | $80.30M | $75.59M | $72.86M | $67.78M | $67.34M | $60.37M | $55.10M | $36.70M | $34.54M | $31.12M | $20.70M | $31.12M | $29.73M | $30.97M |
Avg Forecast | $142.14M | $137.32M | $133.50M | $121.98M | $129.58M | $125.24M | $122.62M | $111.68M | $116.64M | $109.82M | $100.27M | $93.35M | $91.97M | $84.36M | $83.05M | $75.80M | $73.94M | $66.41M | $68.08M | $61.92M | $62.52M | $54.00M | $48.07M | $32.67M | $32.20M | $23.88M | $17.08M | $30.61M | $29.57M | $30.06M |
High Forecast | $148.27M | $143.24M | $139.25M | $127.23M | $135.16M | $130.64M | $127.90M | $117.00M | $117.72M | $110.27M | $100.27M | $93.35M | $95.93M | $85.67M | $86.63M | $79.07M | $76.76M | $66.41M | $68.08M | $61.92M | $62.52M | $54.00M | $48.07M | $32.67M | $32.20M | $23.88M | $17.08M | $30.61M | $29.57M | $30.06M |
Low Forecast | $134.90M | $130.32M | $126.69M | $115.76M | $122.97M | $118.86M | $116.37M | $106.48M | $115.38M | $109.36M | $100.27M | $93.35M | $87.28M | $83.08M | $78.82M | $71.94M | $71.17M | $66.41M | $68.08M | $61.92M | $62.52M | $54.00M | $48.07M | $32.67M | $32.20M | $23.88M | $17.08M | $30.61M | $29.57M | $30.06M |
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.07% | 1.09% | 1.09% | 1.09% | 1.14% | 1.07% | 1.09% | 1.08% | 1.12% | 1.15% | 1.12% | 1.07% | 1.30% | 1.21% | 1.02% | 1.01% | 1.03% |
Forecast
Veracyte EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.03M | - | $-1.19M | $-3.83M | $1.14M | $-3.36M | $-5.34M | $-7.75M | $-4.91M | $-9.28M | $-4.63M | $-43.06M | $2.11M | $-2.08M | $-9.00M | $-9.69M | $-6.10M | $295.00K |
Avg Forecast | $-20.43M | $-19.74M | $-19.19M | $-17.53M | $-18.63M | $-18.00M | $-17.63M | $-16.06M | $-16.77M | $-15.79M | $-14.41M | $-20.42M | $-13.22M | $-12.13M | $-11.94M | $-18.56M | $-5.74M | $-7.78M | $-7.97M | $-16.87M | $-7.32M | $-6.32M | $-5.63M | $-135.64M | $-3.77M | $-2.80M | $-2.00M | $-7.75M | $-3.46M | $-3.52M |
High Forecast | $-19.39M | $-18.73M | $-18.21M | $-16.64M | $-17.68M | $-17.09M | $-16.73M | $-15.31M | $-16.59M | $-15.72M | $-14.41M | $-16.33M | $-12.55M | $-11.94M | $-11.33M | $-14.85M | $-4.59M | $-7.78M | $-7.97M | $-13.50M | $-7.32M | $-6.32M | $-5.63M | $-108.51M | $-3.77M | $-2.80M | $-2.00M | $-6.20M | $-3.46M | $-3.52M |
Low Forecast | $-21.31M | $-20.59M | $-20.02M | $-18.29M | $-19.43M | $-18.78M | $-18.39M | $-16.82M | $-16.92M | $-15.85M | $-14.41M | $-24.50M | $-13.79M | $-12.32M | $-12.45M | $-22.27M | $-6.89M | $-7.78M | $-7.97M | $-20.25M | $-7.32M | $-6.32M | $-5.63M | $-162.77M | $-3.77M | $-2.80M | $-2.00M | $-9.30M | $-3.46M | $-3.52M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.38% | - | 0.10% | 0.21% | -0.20% | 0.43% | 0.67% | 0.46% | 0.67% | 1.47% | 0.82% | 0.32% | -0.56% | 0.74% | 4.50% | 1.25% | 1.76% | -0.08% |
Forecast
Veracyte Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-28.29M | $-29.62M | $-8.40M | $-5.68M | $-3.84M | $-8.72M | $-9.53M | $-14.46M | $-10.53M | $-14.13M | $-9.04M | $-41.87M | $26.86K | $-4.12M | $-11.03M | $-11.72M | $-7.46M | $-730.00K |
Avg Forecast | $22.64M | $20.10M | $19.04M | $15.36M | $17.52M | $15.18M | $14.34M | $9.82M | $8.89M | $2.55M | $-1.29M | $-20.41M | $-7.87M | $-11.49M | $-11.95M | $-18.56M | $-12.30M | $-19.93M | $-17.20M | $-16.87M | $-12.39M | $-13.12M | $-19.41M | $-131.88M | $-7.46M | $-16.20M | $-20.53M | $-9.37M | $-6.30M | $-5.66M |
High Forecast | $23.91M | $21.23M | $20.10M | $16.22M | $18.51M | $16.03M | $15.14M | $11.45M | $9.53M | $2.69M | $-1.20M | $-16.33M | $2.25M | $-9.20M | $-11.16M | $-14.85M | $-9.84M | $-19.93M | $-17.20M | $-13.50M | $-12.39M | $-13.12M | $-19.41M | $-105.51M | $-7.46M | $-16.20M | $-20.53M | $-7.50M | $-6.30M | $-5.66M |
Low Forecast | $21.14M | $18.77M | $17.77M | $14.34M | $16.36M | $14.18M | $13.39M | $8.18M | $8.26M | $2.38M | $-1.36M | $-24.50M | $-14.62M | $-13.03M | $-12.62M | $-22.27M | $-14.77M | $-19.93M | $-17.20M | $-20.25M | $-12.39M | $-13.12M | $-19.41M | $-158.26M | $-7.46M | $-16.20M | $-20.53M | $-11.25M | $-6.30M | $-5.66M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.59% | 2.58% | 0.70% | 0.31% | 0.31% | 0.44% | 0.55% | 0.86% | 0.85% | 1.08% | 0.47% | 0.32% | -0.00% | 0.25% | 0.54% | 1.25% | 1.18% | 0.13% |
Forecast
Veracyte SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $46.89M | $40.68M | $50.80M | $48.59M | $42.34M | $43.28M | $43.80M | $44.15M | $41.06M | $47.46M | $34.71M | $62.17M | $33.84M | $19.11M | $21.14M | $25.03M | $22.40M | $19.35M |
Avg Forecast | $95.76M | $92.51M | $89.94M | $82.18M | $87.30M | $84.38M | $82.61M | $75.24M | $78.58M | $73.98M | $67.55M | $63.05M | $61.96M | $56.83M | $55.95M | $57.32M | $47.99M | $44.54M | $45.66M | $52.11M | $41.93M | $36.22M | $32.24M | $21.91M | $21.60M | $16.02M | $11.45M | $20.02M | $19.83M | $20.16M |
High Forecast | $99.89M | $96.50M | $93.81M | $85.72M | $91.06M | $88.01M | $86.17M | $78.82M | $79.31M | $74.29M | $67.55M | $75.66M | $64.63M | $57.72M | $58.36M | $68.79M | $57.59M | $44.54M | $45.66M | $62.53M | $41.93M | $36.22M | $32.24M | $21.91M | $21.60M | $16.02M | $11.45M | $24.03M | $19.83M | $20.16M |
Low Forecast | $90.88M | $87.80M | $85.35M | $77.99M | $82.85M | $80.07M | $78.40M | $71.73M | $77.73M | $73.68M | $67.55M | $50.44M | $58.80M | $55.97M | $53.10M | $45.86M | $38.39M | $44.54M | $45.66M | $41.69M | $41.93M | $36.22M | $32.24M | $21.91M | $21.60M | $16.02M | $11.45M | $16.02M | $19.83M | $20.16M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.72% | 0.91% | 0.85% | 0.88% | 0.97% | 0.96% | 0.85% | 0.98% | 1.31% | 1.08% | 2.84% | 1.57% | 1.19% | 1.85% | 1.25% | 1.13% | 0.96% |
Forecast
Veracyte EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 1 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.39 | $-0.41 | $-0.12 | $-0.08 | $-0.05 | $-0.12 | $-0.13 | $-0.20 | $-0.15 | $-0.20 | $-0.13 | $-0.66 | - | $-0.08 | $-0.22 | $-0.24 | $-0.15 | $-0.02 |
Avg Forecast | $0.29 | $0.26 | $0.24 | $0.20 | $0.22 | $0.19 | $0.18 | $0.13 | $0.11 | $0.03 | $-0.02 | $-0.16 | $-0.10 | $-0.15 | $-0.15 | $-0.13 | $-0.15 | $-0.26 | $-0.22 | $-0.23 | $-0.16 | $-0.17 | $-0.25 | $-0.12 | $-0.10 | $-0.21 | $-0.27 | $-0.20 | $-0.08 | $-0.07 |
High Forecast | $0.30 | $0.27 | $0.26 | $0.21 | $0.24 | $0.20 | $0.19 | $0.15 | $0.12 | $0.03 | $-0.02 | $-0.15 | $0.03 | $-0.12 | $-0.14 | $-0.13 | $-0.14 | $-0.26 | $-0.22 | $-0.23 | $-0.16 | $-0.17 | $-0.25 | $-0.12 | $-0.10 | $-0.21 | $-0.27 | $-0.20 | $-0.08 | $-0.07 |
Low Forecast | $0.27 | $0.24 | $0.23 | $0.18 | $0.21 | $0.18 | $0.17 | $0.10 | $0.11 | $0.03 | $-0.02 | $-0.17 | $-0.19 | $-0.17 | $-0.16 | $-0.14 | $-0.16 | $-0.26 | $-0.22 | $-0.23 | $-0.16 | $-0.17 | $-0.25 | $-0.12 | $-0.10 | $-0.21 | $-0.27 | $-0.20 | $-0.08 | $-0.07 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.89% | 2.80% | 0.79% | 0.59% | 0.35% | 0.46% | 0.58% | 0.86% | 0.93% | 1.18% | 0.52% | 5.50% | -0.00% | 0.38% | 0.83% | 1.22% | 1.84% | 0.20% |
Forecast
Veracyte Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $2.49 | $33.86 | 1259.84% | Buy |
ENTA | Enanta Pharmaceuticals | $5.58 | $65.67 | 1076.88% | Buy |
KROS | Keros Therapeutics | $16.10 | $101.00 | 527.33% | Buy |
SLDB | Solid Biosciences | $4.14 | $17.50 | 322.71% | Buy |
GPCR | Structure Therapeutics | $27.76 | $99.00 | 256.63% | Buy |
ANAB | AnaptysBio | $14.60 | $49.83 | 241.30% | Buy |
RCKT | Rocket Pharmaceuticals | $12.56 | $38.67 | 207.88% | Buy |
QURE | uniQure | $17.94 | $53.67 | 199.16% | Buy |
KURA | Kura Oncology | $8.73 | $19.00 | 117.64% | Buy |
SNDX | Syndax Pharmaceuticals | $14.37 | $30.60 | 112.94% | Buy |
IDYA | IDEAYA Biosciences | $26.00 | $53.33 | 105.12% | Buy |
MRUS | Merus | $43.16 | $81.25 | 88.25% | Buy |
CYTK | Cytokinetics | $49.36 | $90.00 | 82.33% | Buy |
REPL | Replimune Group | $12.62 | $19.00 | 50.55% | Buy |
PTGX | Protagonist Therapeutics | $39.57 | $57.33 | 44.88% | Buy |
MGTX | MeiraGTx | $6.42 | $9.00 | 40.19% | Buy |
CRNX | Crinetics Pharmaceuticals | $53.15 | $69.00 | 29.82% | Buy |
RYTM | Rhythm Pharmaceuticals | $59.62 | $67.60 | 13.38% | Buy |
VRDN | Viridian Therapeutics | $20.19 | $22.75 | 12.68% | Buy |
VCYT | Veracyte | $41.91 | $35.00 | -16.49% | Buy |